Literature DB >> 3325931

Ciprofloxacin for respiratory tract infection with Pseudomonas aeruginosa.

M J Haverkorn1.   

Abstract

Thirty one patients were treated with oral ciprofloxacin for bronchitis with Pseudomonas aeruginosa. Twenty eight patients had permanent and 14 transient risk factors. Nine patients had a hospital infection with Pseudomonas aeruginosa. Sixteen patients were cured, complete or partial, but Pseudomonas aeruginosa persisted or recurred in 19 patients. Patients with hospital infection did better than other patients. There was a significant decrease in in vitro susceptibility of persisting strains of Pseudomonas aeruginosa to ciprofloxacin and a tendency of recovery of susceptibility for the drug after treatment.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3325931     DOI: 10.1007/bf02075264

Source DB:  PubMed          Journal:  Pharm Weekbl Sci        ISSN: 0167-6555


  5 in total

1.  Antibacterial activities of ciprofloxacin, norfloxacin, oxolinic acid, cinoxacin, and nalidixic acid.

Authors:  A L Barry; R N Jones; C Thornsberry; L W Ayers; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1984-05       Impact factor: 5.191

2.  Oral ciprofloxacin compared with conventional intravenous treatment for Pseudomonas aeruginosa infection in adults with cystic fibrosis.

Authors:  M E Hodson; C M Roberts; R J Butland; M J Smith; J C Batten
Journal:  Lancet       Date:  1987-01-31       Impact factor: 79.321

3.  In vitro activity of Bay 09867, a new quinoline derivative, compared with those of other antimicrobial agents.

Authors:  R Wise; J M Andrews; L J Edwards
Journal:  Antimicrob Agents Chemother       Date:  1983-04       Impact factor: 5.191

4.  Oral ciprofloxacin therapy of infections due to Pseudomonas aeruginosa.

Authors:  B E Scully; H C Neu; M F Parry; W Mandell
Journal:  Lancet       Date:  1986-04-12       Impact factor: 79.321

5.  Use of ciprofloxacin in the treatment of Pseudomonas aeruginosa infections.

Authors:  F Follath; M Bindschedler; M Wenk; R Frei; H Stalder; H Reber
Journal:  Eur J Clin Microbiol       Date:  1986-04       Impact factor: 3.267

  5 in total
  1 in total

Review 1.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.